Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TF0023 for COVID-19 in Hospitalized Adults
NCT05212818Phase 2Terminated
- Sponsor
- Techfields Inc.
- Start
- May 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of 2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride in COVID-19 pneumonia, sponsored by Techfields Inc.. Started May 2022; status: terminated.
02
Drugs
2-(diethylamino)ethyl 2-acetyloxybenzoate hydrochloride
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05212818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212818.